Furthermore, a recent study of Sun et al. demonstrated that the GPX4 inhibitor RSL3, was able to downregulate MACC1 gene expression at the mRNA and protein level as well as reduce the expression of GPX4 in CRC cells [215]. This evidence concerns the gene MACC1 and colorectal carcinoma.